Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

Rhea-AI Summary

Oncternal Therapeutics (Nasdaq: ONCT) has announced its participation in the Jefferies Healthcare Conference from June 8-10, 2022. The company's CEO, James Breitmeyer, will present a corporate overview on June 8th at 9:30 AM ET, and one-on-one meetings will be available.

The company focuses on developing innovative oncology therapies, with lead programs targeting ROR1 through investigational drugs like zilovertamab and ONCT-808. For more information, visit oncternal.com.

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Jefferies Healthcare Conference being held June 8-10, 2022.

James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer, will present a corporate overview on Wednesday, June 8th at 9:30am (ET), and the Company will be available for one-on-one meetings.

The webcast will be available online at investor.oncternal.com.

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The lead clinical program is zilovertamab, an investigational monoclonal antibody designed to inhibit ROR1, a type I tyrosine kinase-like orphan receptor. Zilovertamab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), in investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The early-stage pipeline also includes ONCT-534, a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration resistant prostate cancer, including those with clinically important resistance to approved androgen receptor inhibitors. More information is available at https://oncternal.com/.

Contact Information:

Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com

Media
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
cdavis@lifesciadvisors.com

FAQ

What is Oncternal Therapeutics announcing for the Jefferies Healthcare Conference?

Oncternal Therapeutics will participate in the Jefferies Healthcare Conference from June 8-10, 2022, with a presentation scheduled for June 8th at 9:30 AM ET.

Who will represent Oncternal at the Jefferies Healthcare Conference?

James Breitmeyer, M.D., Ph.D., the President and CEO of Oncternal Therapeutics, will present at the conference.

What is the focus of Oncternal Therapeutics?

Oncternal Therapeutics focuses on developing novel oncology therapies for cancers with critical unmet medical needs, primarily targeting hematological malignancies and prostate cancer.

What is zilovertamab?

Zilovertamab is an investigational monoclonal antibody designed to inhibit ROR1, currently being evaluated in clinical trials for various cancers.

Where can I watch the Oncternal presentation?

The Oncternal presentation will be available online at the investor portion of their website.